期刊
AMERICAN JOURNAL OF MEDICINE
卷 116, 期 -, 页码 30-38出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjmed.2003.10.018
关键词
-
In individuals with diabetes mellitus, higher risk for renal and cardiovascular disease is seen with blood pressure levels >130/80 mm Hg. Findings of several studies, as well as new guidelines, indicate that individuals with diabetes will benefit from more aggressive treatment of hypertension. Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, diuretics, beta-adrenoceptor blockers, and calcium-channel blockers are effective antihypertensive agents in type 2 diabetes. Moreover, combinations of these agents Are frequently required to reach the target blood pressure of <130/80 mm Hg and reduce risk for renal and cardiovascular events. All of these agents have demonstrated benefits in treating patients. Clinical, evidence also indicates that the new Vasodilating beta-blockers offer advantages beyond blood-pressure control, including cardiovascular risk reduction without exacerbating metabolic parameters. With increased awareness of the need for aggressive treatment of hypertension, clinicians can provide significant benefit to their, patients with diabetes. The new beta-blockers may play An important role in achieving blood pressure goals.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据